瑞莎珠单抗临床结果积极;瑞利珠单抗Ⅲ期研究达到主要终点

关键词
C5抑制剂 2型糖尿病 IgA 结核分枝杆菌 系统性红斑狼疮 奥布替尼 本瑞利珠单抗 瑞莎珠单抗 PLpro小分子抑制剂
#今日行业热点#
①The Lancet:Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
临床试验:补体因子C5抑制剂Avacincaptad Pegol (ACP)用于地图样萎缩(GA)患者的疗效和安全性(GATHER2):一项为期12个月的随机、双盲、Ⅲ期试验结果
DOI: 10.1016/S0140-6736(23)01583-0
②The Lancet:NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
NALIRIFOX与白蛋白结合型紫杉醇和吉西他滨在初治转移性胰腺导管腺癌患者中的比较(NAPOLI 3):一项随机、开放标签、3期试验
DOI: 10.1016/S0140-6736(23)01366-1
③The Lancet Diabetes and Endocrinology:Current insights and emerging trends in early-onset type 2 diabetes
综述:早发2型糖尿病(T2DM)的现状和新趋势
DOI: 10.1016/S2213-8587(23)00225-5
④The Lancet Gastroenterology and Hepatology:Serum anti-tissue transglutaminase IgA and prediction of duodenal villous atrophy in adults with suspected coeliac disease without IgA deficiency (Bi.A.CeD): a multicentre, prospective cohort study
临床研究:血清抗组织转谷氨酰胺酶IgA与无IgA缺陷的疑似乳糜泻成人的十二指肠绒毛萎缩的预测(Bi.A.CeD):一项多中心、前瞻性队列研究
DOI: 10.1016/S2468-1253(23)00205-4
⑤The Lancet Microbe:Accuracy of upper respiratory tract samples to diagnose Mycobacterium tuberculosis: a systematic review and meta-analysis
临床研究:上呼吸道样本诊断结核分枝杆菌的准确性:一项系统综述和荟萃分析
DOI: 10.1016/S2666-5247(23)00190-8
⑥The Lancet Rheumatology:Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study
系统性红斑狼疮患者皮质类固醇减量和免疫抑制治疗后低疾病活动度、缓解和完全缓解对发作的影响:一项多国队列研究
DOI: 10.1016/S2665-9913(23)00209-6
⑦布鲁顿酪氨酸激酶(BTK)抑制剂奥布替尼用于复发/难治性边缘区淋巴瘤(MZL)的临床研究结果积极
⑧IL-5Rα单抗本瑞利珠单抗(benralizumab)用于嗜酸性肉芽肿性多血管炎(EGPA)附加维持治疗的III期MANDARA研究达到主要终点
⑨IL-23抑制剂瑞莎珠单抗(risankizumab)用于中重度活动性克罗恩病(CD)的Ⅲ期临床(SEQUENCE)达到双主要终点和所有次要终点
⑩清华大学与复旦大学合作的木瓜蛋白酶样蛋白酶(PLpro)小分子抑制剂HL-21获国家药监局临床许可,有望为多种新冠病毒毒株细胞感染提供新选择
科学探索的世界充满挑战,AtaGenix致敬每一位拓荒者,更致力于成为您信赖的合作伙伴!